Viatris Company Profile

What is the competitive landscape for VIATRIS

VIATRIS has twenty-seven approved drugs.

There are five US patents protecting VIATRIS drugs.

There are fifty-seven patent family members on VIATRIS drugs in twenty-five countries and one hundred and twenty-two supplementary protection certificates in seventeen countries.

Summary for Viatris

International Patents:	57
US Patents:	5
Tradenames:	25
Ingredients:	19
NDAs:	27

Drugs and US Patents for Viatris

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	EDLUAR	zolpidem tartrate	TABLET;SUBLINGUAL	021997-002	Mar 13, 2009	AB	RX	Yes	Yes	9,597,281
Viatris	EPIPEN JR.	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	019430-002	Dec 22, 1987	AB	RX	Yes	Yes
Viatris	EDLUAR	zolpidem tartrate	TABLET;SUBLINGUAL	021997-001	Mar 13, 2009	AB	RX	Yes	No	9,597,281
Viatris	REVATIO	sildenafil citrate	SOLUTION;INTRAVENOUS	022473-001	Nov 18, 2009	AP	RX	Yes	Yes
Viatris	ZOLOFT	sertraline hydrochloride	CONCENTRATE;ORAL	020990-001	Dec 7, 1999	AA	RX	Yes	Yes
Viatris	CARDURA XL	doxazosin mesylate	TABLET, EXTENDED RELEASE;ORAL	021269-002	Feb 22, 2005		RX	Yes	Yes

Expired US Patents for Viatris

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-002	Dec 30, 1991	5,744,501
Viatris	NORVASC	amlodipine besylate	TABLET;ORAL	019787-001	Jul 31, 1992	4,572,909*PED
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-001	Mar 27, 1998	6,469,012*PED
Viatris	NITROSTAT	nitroglycerin	TABLET;SUBLINGUAL	021134-001	May 1, 2000	6,500,456
Viatris	ZOLOFT	sertraline hydrochloride	CONCENTRATE;ORAL	020990-001	Dec 7, 1999	5,744,501
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-004	Dec 30, 1991	4,962,128*PED

Paragraph IV (Patent) Challenges for VIATRIS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection (Auto-injector)	0.15 mg/0.3 mL and 0.3 mg/0.3 mL		2008-11-21
	Nasal Spray	205.5 mcg/spray		2011-12-15
	Tablets	100 mg		2004-10-25
	Sublingual Tablets	0.3 mg, 0.4 mg and 0.6 mg		2005-10-19
	CapsulesInhalation Solution	0.02 mg/2 mL		2009-01-21
	Capsules	20 mg, 40 mg, 60 mg and 80 mg		2005-02-07
	Injection (Auto-injector)	0.15 mg/0.3 mL and 0.3 mg/0.3 mL		2008-11-21
	Inhalation Solution	300 mg/5 mL		2009-06-29
	Tablets	25 mg and 50 mg		2004-11-19
	Sublingual Tablets	5 mg and 10 mg		2010-04-29
	Sublingual Tablets	0.6 mg		2011-12-29
	Tablets	150 mg and 200 mg		2005-11-09

International Patents for Viatris Drugs

Country	Patent Number	Estimated Expiration
South Korea	20070104884
World Intellectual Property Organization (WIPO)	2004091707
Japan	5607291
Japan	4542090
Denmark	2522365
South Africa	200704902

Supplementary Protection Certificates for Viatris Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0402407	97C0005	Belgium		PRODUCT NAME: ESTRADIOL HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: 298 IS 190 F 15 19960806; FIRST REGISTRATION: GB PL/0053/0241 19950711
0398460	SPC/GB04/032	United Kingdom		PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
2435024	CR 2021 00014	Denmark		PRODUCT NAME: KOMBINATION AF FORMOTEROL, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, SOLVATER ELLER ENANTIOMERE DERAF, GLYCOPYRROLAT, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, SOLVATER ELLER ENANTIOMERE DERAF, OG BUDESONID, HERUNDER...; REG. NO/DATE: EU/1/20/1498 20201210
0463756	C990005	Netherlands		PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622
0503785	C300486	Netherlands		PRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216
0473687	3/1999	Austria		PRODUCT NAME: FOSPHENYTOIN-NATRIUM; NAT. REGISTRATION NO/DATE: 1-22664 19980728; FIRST REGISTRATION: GB 00019/0157 19980204

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Viatris
• Viatris Specialty

Viatris: Market Position, Strengths & Strategic Insights

Last updated: February 19, 2026

What is Viatris's Core Business and Market Position?

Viatris Inc. is a global pharmaceutical company formed in November 2020 through the merger of Pfizer's Upjohn business and Mylan N.V. The company operates across three key segments: Branded, Generics, and Biosimil. Viatris's market position is characterized by its broad portfolio of established medicines, including both branded and generic products, and a significant global commercial infrastructure.

The company holds leadership positions in several therapeutic areas, particularly in cardiovascular, central nervous system, and respiratory markets. Its generics segment is a significant contributor, offering a wide range of affordable medicines. The biosimil segment represents a strategic growth area, aiming to expand access to complex biologic therapies.

In terms of revenue, Viatris reported total net sales of $15.7 billion for the fiscal year 2023. The Generics segment accounted for approximately 53% of this revenue ($8.3 billion), followed by the Branded segment at 37% ($5.8 billion), and Biosimil at 10% ($1.6 billion) [1]. This revenue breakdown highlights the company's historical reliance on its generics business while indicating growth potential in branded and biosimilar products.

What are Viatris's Primary Strengths?

Viatris possesses several key strengths that underpin its competitive standing.

Extensive Product Portfolio

Viatris has an extensive portfolio of approximately 1,400 products, covering a wide range of therapeutic areas. This includes established brands, generic drugs, and biosimil products. This breadth allows Viatris to serve diverse patient needs and market demands globally.

Notable branded products include Lipitor (atorvastatin calcium), Norvasc (amlodipine besylate), and Viagra (sildenafil citrate), which collectively generated approximately $1.3 billion in net sales in 2023 [1]. The company also has a robust generics pipeline and a significant number of approved generic products.

Global Commercial Infrastructure

Viatris operates in over 165 countries and territories, supported by a global commercial infrastructure. This includes manufacturing facilities, research and development centers, and a sales force capable of reaching diverse markets. This established global footprint is a significant barrier to entry for new competitors.

The company has manufacturing sites in the United States, Europe, India, and China, among other locations, enabling diversified production and supply chain resilience.

Strategic Partnerships and Licensing

Viatris leverages strategic partnerships and licensing agreements to expand its product offerings and market access. The company has engaged in collaborations with other pharmaceutical firms for co-development, co-promotion, and distribution rights. For instance, Viatris has agreements to market biosimil versions of key biologic drugs.

Supply Chain and Manufacturing Expertise

The company benefits from its legacy Upjohn and Mylan businesses, which provided deep expertise in complex manufacturing processes and supply chain management. This allows Viatris to produce a high volume of diverse pharmaceutical products efficiently and cost-effectively. This is particularly crucial for its generics and biosimilar segments, where cost of goods is a significant factor.

Focus on Established Medicines

While investing in new development, Viatris maintains a strong focus on maximizing the value of its established medicines. This includes lifecycle management, market optimization, and addressing unmet needs within its existing portfolio. This strategy provides a stable revenue base while pursuing growth opportunities.

What are Viatris's Key Strategic Initiatives and Challenges?

Viatris is actively pursuing strategic initiatives to drive future growth and navigate the complexities of the pharmaceutical market.

Biosimilar and Specialty Product Expansion

A core strategic pillar for Viatris is the expansion of its biosimilar and specialty product portfolio. The company aims to leverage its expertise to bring high-quality, affordable biosimil alternatives to market, targeting blockbuster biologic drugs as their patents expire.

In 2023, Viatris launched several biosimilar products, including those for adalimumab and insulin glargine, in key markets. The company has a pipeline of biosimilar candidates in development, including those targeting oncology and immunology indications. The biosimilar market is projected to grow significantly, and Viatris is positioned to capture a share of this growth.

Divestitures and Portfolio Optimization

Viatris has undertaken portfolio optimization efforts, including the divestiture of non-core assets. In December 2022, the company completed the divestiture of its China sterile injectables business to Xiamen Kingdomway Group Company for approximately $250 million [2]. These divestitures aim to streamline operations, reduce debt, and focus resources on higher-growth areas.

Digital Transformation and Operational Efficiency

The company is investing in digital transformation to enhance operational efficiency, improve customer engagement, and accelerate product development. This includes leveraging data analytics for market insights, optimizing manufacturing processes through automation, and enhancing digital customer engagement platforms.

Market Access and Pricing Pressures

Viatris faces significant challenges related to market access and pricing pressures, particularly in its generics segment. Governments and payers globally are implementing measures to control healthcare costs, which directly impacts generic drug pricing. Navigating these complex pricing and reimbursement environments is crucial for sustained profitability.

Regulatory and Competitive Landscape

The pharmaceutical industry is subject to stringent regulatory oversight. Viatris must ensure compliance with evolving regulatory requirements across its global operations. The competitive landscape is also dynamic, with increasing competition from both branded and generic manufacturers, as well as new entrants in the biosimilar space.

Supply Chain Resilience

Recent global events have highlighted the importance of supply chain resilience. Viatris continues to invest in diversifying its supply chain and ensuring the consistent availability of its medicines, particularly for essential generic drugs.

What are the Future Outlook and Investment Considerations for Viatris?

Viatris's future outlook is contingent on its ability to execute its strategic initiatives while mitigating inherent industry challenges.

Growth Drivers

The primary growth drivers for Viatris are expected to be its biosimilar portfolio, the expansion of its branded segment through new launches and in-licensing, and the continued optimization of its generics business. The global biosimilar market is projected to grow at a compound annual growth rate (CAGR) of approximately 12-15% over the next five years, driven by patent expiries of major biologics and increasing healthcare costs [3]. Viatris's strategic focus on this segment positions it to capitalize on this trend.

The company's branded segment is expected to benefit from the continued performance of key established brands and the introduction of new specialty products. Viatris has indicated a focus on developing and acquiring differentiated branded medicines, particularly in areas with unmet medical needs.

Financial Performance

Viatris has been focused on deleveraging its balance sheet and improving free cash flow. The company aims to reduce net debt by a substantial amount through ongoing operational improvements and strategic divestitures. Investors will be looking for sustained free cash flow generation and a clear path towards deleveraging.

For the fiscal year 2023, Viatris reported adjusted EBITDA of $3.4 billion [1]. The company has provided guidance for 2024, expecting net sales between $13.1 billion and $13.7 billion, reflecting anticipated headwinds from biosimilar launches and the ongoing optimization of its generics business [4].

Investment Considerations

Investors in Viatris should consider the company's diversified portfolio, its global reach, and its strategic pivot towards biosimil and specialty products. The company's ability to successfully launch and commercialize biosimil products will be a key determinant of its future success.

However, potential investors must also assess the risks associated with pricing pressures in the generics market, regulatory hurdles, and the intense competition within the pharmaceutical sector. The company's execution on its debt reduction targets and its ability to generate consistent free cash flow will be critical metrics.

The long-term success will depend on Viatris's ability to innovate, adapt to evolving market dynamics, and effectively manage its complex global operations.

Key Takeaways

• Viatris is a global pharmaceutical company formed from the merger of Pfizer's Upjohn and Mylan, operating in Branded, Generics, and Biosimilar segments.
• The company's strengths include an extensive product portfolio, a robust global commercial infrastructure, expertise in supply chain and manufacturing, and strategic licensing.
• Key strategic initiatives focus on expanding its biosimilar and specialty product portfolio, optimizing its business through divestitures, and driving operational efficiency via digital transformation.
• Viatris faces challenges from market access and pricing pressures, regulatory complexities, and intense competition.
• Future growth is expected to be driven by biosimil launches and the branded segment, with a focus on deleveraging the balance sheet and generating free cash flow.

Frequently Asked Questions

1. What is Viatris's primary strategy for future growth? Viatris's primary strategy for future growth is centered on expanding its biosimilar and specialty product portfolio, complemented by the optimization of its existing generics and branded businesses.

2. How does Viatris manage pricing pressures in the generics market? Viatris manages pricing pressures in the generics market through operational efficiencies, portfolio diversification, and strategic market access initiatives to ensure competitive cost structures and value propositions.

3. What is the significance of Viatris's biosimilar segment? The biosimilar segment is of significant strategic importance as it represents a key area for future revenue growth, leveraging patent expirations of major biologic drugs to offer affordable alternatives.

4. What are the main therapeutic areas Viatris targets? Viatris has leadership positions in cardiovascular, central nervous system, and respiratory therapeutic areas, among others, and is expanding its focus in oncology and immunology through its biosimilar pipeline.

5. What is Viatris's approach to debt management? Viatris is actively pursuing a strategy to deleverage its balance sheet through ongoing operational improvements and strategic divestitures to reduce its overall debt levels.

Citations

[1] Viatris Inc. (2024). Viatris Reports Fourth Quarter and Full Year 2023 Results. Retrieved from https://investors.viatris.com/news-releases/news-release-details/viatris-reports-fourth-quarter-and-full-year-2023-results

[2] Viatris Inc. (2022). Viatris Completes Divestiture of China Sterile Injectables Business. Retrieved from https://investors.viatris.com/news-releases/news-release-details/2022/Viatris-Completes-Divestiture-of-China-Sterile-Injectables-Business/default.aspx

[3] Grand View Research. (2023). Biosimil Market Size, Share & Trends Analysis Report By Product (Monoclonal Antibodies, Recombinant Proteins), By Indication (Cancer, Autoimmune Diseases), By Region, And Segment Forecasts, 2023 - 2030.

[4] Viatris Inc. (2024). Viatris Provides 2024 Financial Guidance. Retrieved from https://investors.viatris.com/news-releases/news-release-details/2024/Viatris-Provides-2024-Financial-Guidance/default.aspx